Blood Flashcards
Sites of Hematopoiesis
Intramedullary: within the bone marrow. Normal in children and adults
Extramedullary: outside the bone marrow- the spleen and liver, normal in the fetus. Abnormal in disease states
Hematopoiesis
Fetal yolk sac at 3 wks gestation develops mesenchymal blood islands
These stem cells migrate to the liver and spleen at week 6-12
Red bone marrow develops bone at the 12th week
Red marrow stops at puberty, long bones only then generate blood
Myeloid cell line (common myeloid progenitor)
Granulocytes (N E B)
Monocytes
RBC
Platelets
Lymphoid progenitor cell line
Dendritic cell
B
T
NK
Maturation of the RBC
Polychromatophilic normoblast (Blast cell) within the bone marrow have nuclei.
The reticulocyte is the blast cell without a nuclei. It still has some ribosomes and is making hemoglobin. It is released from the bone marrow and within hours it becomes RBC.
Erythropoietin Physiology
EPO is released due to hypoxic stimulation of peritubular cells in kidney via colony stimulating factor-E (erythrocyte)
Stimulates the production of RBC via progenitor line as well as release of RBC from bone marrow.
Normal hemoglobin content of RBC cytoplasm
32-36%
Hemoglobin Biochemistry
HbA is 4 globin chains each with a heme molecule. Usually is 2 alpha 2 beta.
Heme is a protophorphyrin ring with 1 atom of Fe2+ which can bind reversibly with 1 molecule of oxygen
Storage of Dietary iron
Within the liver as Ferritin Fe3+ with apoferritin
Within the liver as hemosiderin (partially degraded ferritin)
Storage of iron in bone marrow
Liver stores are transported to the bone marrow as transferrin, which is Fe3 and apotransferrin
Normal Forms of Hemoglobin
HbA2: 2 alpha2, 2 beta2 in adults.
HbF: 2 alpha 2, 2 gamma2 in infants with some A2
RBC senescence
Driven by degradation of metabolic proteins due to the lack of a nucleus over 120 days.
Once enzymes run out the cells lose membrane fluidity, and water enters cells making them spheroid, rigid, and fragile
Extravascular Hemolysis Physiology
In splenic sinusoids: the old RBCs get stuck, and are destroyed by splenic macrophages.
Also occurs in liver.
In bone marrow, unnecessary progenitors are destroyed by BM macrophages.
This causes release of unconjugated bilirubin which gets excreted in hepatic bile.
Also occurs in spleen with IgG reaction on RBC
Intravascular Hemolysis Physiology
Fibrin clots, Immune response etc causing hemoglobinemia
Leukocyte Maturation Times
Neutrophils: 12 hours
Eo; 3.5 days
Monocyte: 3 days
Neutrophil development
Proliferation within the bone marrow consists of myeloblast, promyelocyte, myelocyte, metamyelocyte.
Metamyelocytes can only mature but not proliferate.
Metamyelocytes develop to bands and then neutrophils.
The ‘band’ is the nucleus that is not segmented. Normal is 5% of neutrophils or less in peripheral smear
Neutrophil granule contents
Myeloperioxdase
Lysozyme
Alkaline phosphatase
Eosinophil function
Antigen presenting cell
Releases major basic protein (MBP) and acid phosphatase
Releases other cytokines
Basophil function
Has Surface IgE receptors that cause allergic inflammation
Releases histamine and cytokines
Similar to mast cells
T cell physiology
Proliferation in thymus. Those that do not recognize self antigens go through apoptosis.
If T cell contacts foreign antigen from lymphatic drainage then it becomes sensitized.
May become CD4 helper T cells.
May become CD8 cytotoxic t cells
May be come regulatory T cell to suppress response
B cell physiology
lymphoid progenitor in bone marrow develops to naive B cells, which migrate to germinal centres of lymph tissue.
When exposed to antigens they transform to plasma/memory cells which produce antibodies
NK cell physiology
matures directly from common lymphocyte progenitor and has non specific immunity capable of killing tumour cells or virus infected cells without prior exposure
Control of thrombopoiesis
Thrombopoietin is produced by the kidney, liver and smooth muscle
It binds to receptors on platelets and is destroyed. The lower the number of platelets the more the hormone circulates.
Platelet plasma membrane structure
Contains negative glycocalyx carbohydrates making it very negative and repelling other platelets
Has proteins for binding collagen directly
Has proteins for binding vWF
FVIII
Cofactor that circulates bound to vWF, produced in liver
Binds with FIX
Extremely unstable unless bound to vWF.
FV
Cofactor produced by megakaryocytes, stored in alpha granules, 20% circulates in platelets
Binds to FX
vWF Functions
Carries FVIII
Binds to collagen
Binds to GpIb on platelets especially in high shear stress environments
Has a heparin binding site
ADAMTS-13
Breaks down vWF multimers
Deficiency causes familial TTP
Can be inhibited by inflammation causing immune-mediated TTP
vWF Disease, Inherited
Autosomal dominant resulting in decreased vWF and mucocutaneous bleeding. Made in endothelium and megakaryocytes
Type 1: asymptomatic, heterozygous
Type 2: Qualitative, mild symptoms that generate multimers
Type 3: Homozygous, hemorrhage
vWf Disease, acquired
Autoantibody generation against vWF, associated with aortic stenosis and VAD
Functions of thrombin
-Fibrinogen to fibrin monomers
-Activates FV,FVIII, IX
-Cross links with FXIII
-Activates platelets, thromboxane
-Endothelial stim: tPA, NO, prostacyclin
-Activates protein C, thrombomodulin
Thrombin is the final serine protease in the cascade
Platelet Granule contents
- ADP causes aggregation
- Epinephrine
- Calcium
- Thromboxane: aggregation and vasoconstriction
- FV
- vWF
Thombomodulin function
Constititutively expressed on endothelial cell surface
Acts as cofactor to the activation of protein C by thrombin
In combination with protein S, proteolytically clears FVIII and FV
Antithrombin III
Inhibits thrombin, and F 9-12 as a serine protease
Produced in the liver
Increased allosteric function of anti FIXa and FXa via minimal heparin pentasaccharide sequence
Extrinsic Clotting pathway
- Exposed TF activates FVII(Serine protease) on endothelial surface
- Happens on negative endothelial surface, with presence of positive Ca ions
- FVIIa acts on X
Intrinsic Clotting pathway
Prekallikrein, HMWK and XII activate in the presence of tissue injury (polyanions, -). Also activated via thrombin
Activates XI, IX.
This complexes with FVIIIa on platelet surface to create tenase complex (IXa+VIIIa), which cleaves X and creates common pathway
Common clotting pathway
Xa+ Va on platelet surface causes thrombin generation
Rosenthal correction factor for pH and temperature
Water increases 0.017 pH unit for every degree decrease in blood
Collection bags of Canadian blood
Buffy coat collection set: whole blood cooled then centrifuged, separating plasma, Buffy coat, and RBC. RBC then LR. Allows for pooled platelet product creation.
Whole blood collection set: cooled, LR (WBC and PLT removed) and then RBC/plasma extracted
Average CBS RBC unit
293 mL containing 56 grams of Hgb, Hct 0.68. One unit typically increases [Hgb] by 10 g/L in adults.
American= 300-400 mL, hot 55-65%, increases hct by 3%
Conditions in which blood products may be returned to inventory
Bag intact, pass visual inspection, maintained an acceptable temperature or the RBC have not been outside of fridge for more than 60 min
CBS RBC shelf life
-42 days from the time of collection
-24 hours if entered without use of sterile connection device, if stored at 1-6C or 4 hours if stored above 6C
-unit irradiated at CBS within 14 days and may be stored for another 14 days
-
CBS RBC unit transportation
1-6 C in temp controlled storage with alarm, fan and continuous monitoring.
1-10C if transport is less than 24h
Must have documentation to allow tracing of each portion of transport.
Manufacture method of CBS pooled platelets
From whole blood via Buffy coat collection method using CPD anticoagulant. Plasma top layer and RBC bottom layers removed, leaving Buffy coat containing PLT and WBC.
4 donations of same ABO group with plasma from one of the same 4 donations (usually male) are pooled then LR.
Pool is Rh neg if all donor units are Rh neg.
Produced within 28 hours of collection, stored for 7 days
Average CBS pooled platelet unit
342 mL with 300 x10^9
Manufacture method of CBS Apheresis platelets, average aperheresis platelets
Flow cytometer separates RBC/WBC from platelets and plasma. Contains 242 mL with 370 X10^9
Use of Apheresis platelets vs pooled Buffy coat platelets
Aperesis is single donor. Can be used for HLA typing when recipient has demonstrated anti-HLA antibodies for platelet refractoriness
Storage of platelets
20-24C under continuous agitation for 7 days since collection
Expires 4 hours after opening unless opened under sterile conditions for aliquot preparation, in which case the aliquots can be stored for 7 days
CBS Frozen plasma manufacture
Whole blood collection in CPD, red cell reduced by centrifugation, either Buffy coat removed via centrifugation or through filtration. CPD FP frozen within 24 hours of collection.
Not considered LR because processing removes cells but remaining plasma has variable WBC
CBS fresh frozen plasma manufacture
Apheresis generation removes plasma, collected and frozen within 8 hours and labelled as apheresis fresh frozen plasma
Difference in use between FP and FFP
AFFP contains 87% of FVIII and 0.7 IU/mL FVIII
FP contains 70-75% of the FVIII and 0.52 IU/mL
Other factors are similar. Therefore AFFP should be used with isolated FVIII or VWF deficiency if recombinant products are unavailable.
FV also reduced in FP.
1 apheresis donation=2 whole blood donations by volume
General indications for plasma transfusion
Bleeding, severe liver disease, DIC, massive transfusion, invasive procedure on warfarin before vit K can work and PCC is not available, rare protein deficiencies, TTP/HUS by plasma exchange, other indications for plasma exchange
Indications for cryosupernatant plasma transfusion
Treatment of TTP and HUS by plasma exchange, or multiple plasma deficiency especially where fibrinogen replacement is not required (eg. warfarin replacement that does not require fibrinogen)
Contraindications of plasma transfusion
- Volume replacement use alone
- single factor deficiency with available recombinant product/virally inactivated product available
- reversal of therapy with INR below 1.8
Contraindications of cryosupernantant plasma transfusion
- conditions that require fibrinogen replacement
- FVIII or VWF replacement